Difference between revisions of "Mepolizumab (Nucala)"
Jump to navigation
Jump to search
(Created page with "=General information= Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). =Preliminary data= ==Hypereosinophilic syndrome (HES)== # Rothenb...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =General information= | + | ==General information== |
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | ||
| − | = | + | ==Diseases for which it is used== |
| + | *[[Hypereosinophilic syndrome (HES)]] | ||
| − | == | + | ==History of changes in FDA indication== |
| − | + | ''No approval for hematology/oncology conditions, at this time.'' | |
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Bosatria, Nucala | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| − | |||
| − | |||
| − | |||
[[Category:Anti-IL-5 antibodies]] | [[Category:Anti-IL-5 antibodies]] | ||
| − | [[Category: | + | [[Category:Hypereosinophilic syndrome medications]] |
| + | |||
| + | [[Category:FDA approved in 2015]] | ||
Latest revision as of 19:47, 27 February 2020
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
History of changes in FDA indication
No approval for hematology/oncology conditions, at this time.
Also known as
- Brand names: Bosatria, Nucala